Study Details
Safety and tolerability study of claudiximab in patients with advanced gastroesophageal cancer
Clinicaltrials.gov ID
Astellas Study ID
GM-IMAB-001
EudraCT ID
N/A
Condition
Advanced/Metastatic Cancer
Phase
Phase 1
Age
18 Years - N/A
Sex
Female & Male
Product
N/A
Type
Interventional
Trial Dates
May 2009 - May 2010
Masking
None (Open Label)
Enrollment number
15
Clinical first-in-human single-dose escalation study evaluating the safety and tolerability of claudiximab (iMAB-362) in hospitalized patients with advanced gastroesophageal cancer. A multi-center, phase I, open-label, i.v. infusion study
Study summary
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for Safety and tolerability study of claudiximab in patients with advanced gastroesophageal cancer? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Johannes Gutenberg Universität, 1.Med Klinik und Poliklinik
Mainz, Germany, 55131
Universitätsklinikum Essen, Innere Klinik (Tumorforschung)
Essen, Germany, 45122
Universität Heidelberg, Nationales Centrum für Tumorerkrankungen (NCT)
Heidelberg, Germany, 69120
Klinikum Rechts-der-Isar, III.Medizinische Klinik und Poliklinik
München, Germany, 81674
Pauls Stradins University
Riga, Latvia, 1002
Piejuras Hospital
Liepaja, Latvia, 3401